SETDB1 and neoplasm: The identification of a SETDB1 inhibitor could provide new hope for the treatment of osteosarcoma by modulating its anti-tumor immune activity and altering its microenvironment, potentially enhancing tumor sensitivity to therapeutic approaches, such as radiotherapy.